Loading
NASDAQHealthcareMedical - Devices
Latest quote
$0.6501
+$0.0266 · +4.27%
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
Previous close
$0.6501
+$0.0266 · +4.27%
Pre-market
$0.60
−$0.0501 · -7.71%
Oct 9, 4:03 AM ET
Regular session · ET · Market data may be delayed.
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
Day range
Current $0.6501
52-week range
Current $0.6501
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
32
Expensive
Sentiment
67
Bullish
Risk
63
High Risk
Momentum
34
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
Day range
Current $0.6501
52-week range
Current $0.6501
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.71M USD | 4.35M USD | 2.43M USD | 377K USD | 500K USD |
| Cost of goods sold | 7.54M USD | 8.27M USD | 8.48M USD | 3.61M USD | 585K USD |
| Gross profit | −2.84M USD | −3.92M USD | −6.05M USD | −3.24M USD | −85K USD |
| Research and development | 5.68B USD | 5.99M USD | 7.25M USD | 11.47M USD | 9.3M USD |
| Selling, general, and administrative | 41.58B USD | 36.62B USD | 35.66M USD | 39.82M USD | 18.04M USD |
| Operating expenses | 46.8M USD | 42.13M USD | 42.43M USD | 52.93M USD | 27.33M USD |
| Interest income | 386K USD | 322K USD | 424K USD | 88K USD | — |
| Interest expense | 22K USD | 26K USD | 416K USD | 8K USD | 659K USD |
| Depreciation and amortization | 872K USD | 1.17M USD | 2.5M USD | 1.94M USD | 4K USD |
| Operating income | −49.64M USD | −46.05M USD | −48.48M USD | −56.17M USD | −27.42M USD |
| Net income | −58.01M USD | −45.53M USD | −52.67M USD | −56.17M USD | −28.08M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.45M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM2.27M0.00%77.7B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF1.82M0.00%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO878.47K0.01%14.04B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO833.65K0.00%18B USD0.06%$112.1-0.10%
iShares Micro-Cap ETFIWC302.89K0.02%1.32B USD0.60%$182.79-0.31%
Vanguard Russell 2000 Growth ETFVTWG158.37K0.01%1.7B USD0.06%$258.14-0.44%
iShares Russell 2500 ETFSMMD47.64K0.00%4B USD0.23%$85.96+0.13%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
